Hand-foot Syndrome Clinical Trial
Official title:
Hydration Based on Thoitaine, Aloe Vera and Calendula, in the Prevention of Hand-Foot Syndrome in Patients Using Capecitabine: TACX Care Trial
Hand-foot syndrome (HFS) is a very common adverse event of many chemotherapeutic agents, especially capecitabine. The HFS can considerably interfere patient quality of life (QoL). The current treatments for hand-foot symptoms no have demonstrated 100% efficacy. And, the dose reduction and treatment interruption are recommended for treatment of HFS. It is known that hydration improves the degree of hand-foot syndrome, as it improves moisture retention and maintain hydration, thereby reducing further desquamation and decreasing infection risks. But so far there is no evidence of a cream that improves incidence. Besides that, clinical trials evaluating the use of urea-based moisturizer in patients treated with capecitabine have not shown efficacy in preventing hand-foot syndrome. The purpose of this study is to evaluate the effectiveness of moisturizer based on Thoitaine, Aloe Vera and Calendula compared to placebo in the prevention of SMP of any degree, in patients using Capecitabine.
The research product, proposed in this study, was developed to meet the specific hydration needs of patients undergoing cancer treatment and is produced from nine main ingredients with natural moisturizing actions based on glycerin, hazelnut extract, shea butter, aloe vera, calendula, chamomile and oat extract and 2 antioxidants (vitamin E and Thoitaine), dermatologically tested and approved. The choice of the product was based, mainly, due to its natural components, whose data from previous studies were extrapolated from radiodermatitis. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04592731 -
Acetylated Natural Nucleotides in Treating Hand-foot Syndrome
|
N/A | |
Completed |
NCT05755646 -
Ice Plant Intensive Cream for the Prevention of Hand-Foot Syndrome in Breast Cancer: Pilot Randomized Controlled Trial
|
N/A | |
Completed |
NCT00446147 -
Study of Pyridoxine for Hand-Foot Syndrome
|
Phase 3 | |
Completed |
NCT01609166 -
Effectiveness Allopurinol Topical Agent Prevention Capecitabine-induced Hand-foot Syndrome
|
Phase 2 | |
Terminated |
NCT03173365 -
The Effect of Topical Brimonidine Tartrate on Hand-foot Syndrome (HFS) in Cancer Patients
|
Phase 2 | |
Recruiting |
NCT04979078 -
Photobiomodulation Therapy in the Management of Hand-foot Syndrome and Hand-foot Skin Reaction
|
N/A | |
Recruiting |
NCT05165069 -
The Efficacy and Safety of Mecobalamin in the Prevention of Capecitabine Induced Hand Foot Syndrome
|
Phase 3 | |
Recruiting |
NCT05348278 -
Urea Cream Prevention for Capecitabine Associated Hand Foot Syndrome
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT05949307 -
The Efficacy of Acupuncture and Laser Acupuncture in Treating Chemotherapy or Target Therapy-induced Hand-foot Syndrome
|
N/A |